Minimizing the Burden of Chronic Kidney Disease

  • March 12, 2021
  • 2:00 PM – 3:00 PM ET
  • Online

Chronic Kidney Disease (CKD) is one of the costliest conditions for health insurance providers and yet continues to result in poor patient outcomes. Simple diagnostic tests and tools that could reduce this burden are underutilized, limiting the potential for improved outcomes, quality improvement, and cost savings.

This webinar will provide information on the magnitude of the problem and will provide an evidence-based approach to risk stratification and segmentation. A case study of a comprehensive CKD intervention by a health insurance provider will be presented.

Attendees will learn about:

  • The impact of CKD on clinical, economic, and quality measures
  • Evidence-based approaches to risk stratification and segmentation
  • Patient types that are most likely to benefit from more comprehensive testing, monitoring and interventions
  • Learnings from a CKD population health intervention that are transferrable to the management of members at highest risk of progression and cost escalation


Patrick James, MD
Chief Clinical Officer, Health Plans and Policy
Quest Diagnostics, Inc.

L. Patrick James, MD, is the Chief Clinical Officer, Health Plans and Policy, at Quest Diagnostics. Prior to assuming this role, he served in other senior leadership roles within Quest. Before joining Quest Diagnostics, Dr. James served as Executive Vice President for Pathology and Laboratory Services at LabOne. He spent nine years with Health Midwest, a 14-hospital integrated delivery system in Kansas City, as Medical Director of Hospital Integration. Dr. James’ experience spans Research Medical Center, St. Joseph Hospital in Denver, Colorado, and National Naval Medical Center in Bethesda, Maryland.

Dr. James earned his Medical Degree with honors from St. Louis University in Missouri.

Joseph Vassalotti, MD
Chief Medical Officer
National Kidney Foundation

Dr. Joseph Vassalotti is the Chief Medical Officer of the National Kidney Foundation (NKF) and Clinical Professor of Medicine in the Division of Nephrology, at Icahn School of Medicine at Mount Sinai –New York.

At NKF, his major focus is implementation of evidence-based clinical practice guidelines in chronic kidney disease (CKD), including the NKF’s Kidney Disease Outcomes Quality Initiative (KDOQI), particularly through guidance of the NKF’s primary care initiative, called CKD intercept.

He received his Medical Degree with Distinction in Research from the State University of New York –Stony Brook School of Medicine, and completed an Internal Medicine Residency and Nephrology Fellowship at the Johns Hopkins Hospital.


Marc Penn, MD, PhD, FACC
Senior Medical Director, Cardiovascular, Metabolic & Endocrine Clinical Franchise
Quest Diagnostics, Inc.

Dr. Marc Penn is the founder of Cleveland HeartLab, which was acquired by Quest Diagnostics in 2017, and is the Medical Director of Quest Diagnostics’ Cardiometabolic Franchise. He is also the Director of Research at Summa Cardiovascular Institute within Summa Health in Akron, Ohio, and Professor of Medicine and Integrative Medical Sciences at the Skirball Laboratory of Cardiovascular Cellular Therapeutics at Northeast Ohio Medical University. Prior to this position, Dr. Penn spent 25 years at the Cleveland Clinic in the Heart and Vascular Institute and was the Director of the Bakken Heart-Brain Institute.

Dr. Penn received both his Medical and Doctorate degrees from Case Western Reserve University in Cleveland, Ohio and proceeded into residency at University Hospitals Case Medical Center. After this, he accepted a fellowship at the Cleveland Clinic in the Department of Cardiology.

" "